RPTR 168 2
Alternative Names: PRIME-IL-12; RPTR-168 2Latest Information Update: 24 Nov 2022
At a glance
- Originator Repertoire Immune Medicines
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cervical cancer; Head and neck cancer
Most Recent Events
- 31 Oct 2022 Discontinued - Phase-I for Cervical cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV)
- 31 Oct 2022 Discontinued - Phase-I for Head and neck cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV)
- 28 Apr 2022 Preclinical pharmacodynamic data in Cancer released by Repertoire